30/06/2008 (Agence Europe) - On Thursday 26 June, the European Medicines Agency (EMEA) recommended a new warning on the use of epoetins in cancer patients. Studies have shown an increased risk of tumour progression in patients who receive epoetin-containing medicines. Consequently, the EMEA recommends blood transfusion to correct anaemia in cancer patients. Prescription of epoetin for patients with chronic renal failure is not affected by this warning. (O.J./transl.rt)